The country may soon get its first nasal vaccine, with Phase 3 of the intranasal trial completed
Bharat Biotech Completes Phase 3 Trial of BBV154 Intranasal Covid Vaccine BBV154 has been shown to be safe and immunogenic, says Bharat Biotech International Ltd.
Bharat Biotech BBV154 Intranasal Anti-covid medicine Phase 3 testing is over. BBV154 has been shown to be safe and immunogenic, says Bharat Biotech International Ltd. The vaccine is now expected to be approved soon. This is India’s first nasal vaccine. This will give more strength in the fight against corona virus.
BBIL Chairman and Managing Director Krishna Ella said recently that they will apply for the license and expect a positive response. If all goes well, people will get this covid vaccine by August this year. If a new variant of Corona comes, it will help to deal with it. Bharat Biotech believes injectable and nasal vaccines could help save lives in the future.
Bharat Biotech Completes Clinical Development for Phase III Trials and Booster Doses for BBV154 Intranasal Covid Vaccine#Bharat Biotech #Covid19 vaccine #PPV154 #Intranasalvaccine #Covid19 pic.twitter.com/oh76drnezz
— BharatBiotech (@BharatBiotech) August 15, 2022